crimeancongo
hemorrhag
fever
cchf
potenti
fatal
tickborn
infecti
diseas
report
countri
part
africa
eastern
europ
asia
human
infect
occur
bite
infect
tick
contact
tissu
blood
virem
anim
cchf
patient
casefat
rate
nearli
incid
geograph
rang
confirm
cchf
case
increas
turkey
first
case
cchf
identifi
number
patient
increas
number
identifi
case
current
iran
case
occur
china
case
identifi
kazakhstan
case
report
present
establish
countermeasur
combat
cchf
cchf
caus
infect
cchf
viru
cchfv
member
genu
nairoviru
famili
bunyavirida
countri
experiment
use
cchfv
requir
biosafeti
level
bsl
contain
viru
triseg
negativesens
singlestrand
rna
genom
form
envelop
virion
l
segment
encod
rnadepend
rna
polymeras
envelop
glycoprotein
gp
nucleocapsid
protein
respect
precursor
gp
cleav
modifi
gener
structur
protein
gn
gc
nonstructur
protein
nsm
structur
protein
form
complex
envelop
interact
host
receptor
initi
infect
primari
target
neutral
antibodi
report
previous
earli
stage
cchfv
infect
depend
ph
cholesterol
furthermor
previous
shown
gc
cytoplasm
tail
virus
famili
bunyavirida
rift
valley
fever
viru
uukuniemi
viru
bunyamwera
viru
crucial
traffick
local
gc
also
gn
vesicular
stomat
indiana
viru
vsv
member
famili
rhabdovirida
nonseg
negativesens
singlestrand
rna
viru
handl
facil
contain
pseudotyp
viral
glycoprotein
onto
vsv
facilit
studi
viral
entri
measur
viru
neutral
activ
contain
fewer
contain
facil
world
pseudotyp
virus
valuabl
tool
especi
studi
diagnosi
highli
pathogen
virus
although
nucleolin
report
candid
receptor
cchfv
still
unclear
factor
requir
cchfv
entri
factor
calciumdepend
ctype
lectin
recogn
glycan
exist
gp
andor
glycolipid
lectin
dcsign
lsectin
mgl
known
entri
factor
sever
virus
includ
human
immunodefici
viru
measl
viru
dengu
viru
sever
acut
respiratori
syndrom
coronaviru
sarscov
filovirus
lassa
viru
shown
member
famili
bunyavirida
includ
phlebovirus
rift
valley
fever
viru
uukuniemi
viru
sever
fever
thrombocytopenia
syndrom
viru
sftsv
use
dcsign
receptor
uukuniemi
viru
shown
bind
directli
dcsign
recognit
glycan
virion
ctype
lectin
result
enhanc
viral
endocytosi
cellular
viral
membran
fuse
cchfv
gn
gc
nglycosyl
site
like
bind
ctype
lectin
present
studi
facil
contain
gener
high
titer
pseudotyp
vsv
bear
cchfv
envelop
gp
surfac
cchfvpv
analyz
mechan
cchfv
cell
entri
use
pseudotyp
viru
cell
atcc
vero
cell
atcc
cell
atcc
cultur
dulbecco
modifi
eagl
medium
dmem
sigma
supplement
vv
fetal
bovin
serum
fb
gibco
jurkat
cell
atcc
cultur
sigma
medium
supplement
vv
fb
jurkat
cell
stabli
express
dcsign
lsectin
prepar
describ
previous
cdna
encod
open
read
frame
cchfv
ibar
strain
gp
clone
pcagg
use
rapid
dna
ligat
kit
roch
gener
pccchfv
gp
construct
plasmid
encod
mutant
gp
carboxyl
termin
region
partial
truncat
stop
codon
introduc
pccchfv
gp
pcrbase
mutagenesi
express
mutant
gp
list
tabl
plasmid
construct
confirm
sequenc
use
abi
prism
genet
analyz
appli
biosystem
pseudotyp
vsv
bear
cchfv
envelop
gp
gener
describ
previous
briefli
cell
transfect
cchfv
gp
plasmid
use
miru
infect
g
g
g
gene
replac
green
fluoresc
protein
gfp
luciferas
gene
respect
multipl
infect
viru
adsorb
h
remov
extens
wash
four
time
serumfre
dmem
h
incub
cultur
medium
cultur
supernat
centrifug
remov
cell
debri
store
use
produc
pseudotyp
viru
gfp
gene
luciferas
gene
bear
viral
envelop
protein
empti
plasmid
pcagg
gfp
express
plasmid
pcgfp
use
vsvpvluc
pseudotyp
vsv
luciferas
gene
bear
vsv
g
mlvpvluc
pseudotyp
vsv
luciferas
gene
bear
murin
leukemia
viru
envelop
protein
lassapvgfp
pseudotyp
vsv
gfp
gene
bear
lassa
viru
envelop
protein
ebovpvgfp
pseudotyp
vsv
gfp
gene
bear
ebola
viru
envelop
protein
gener
describ
previous
quantit
measur
infect
cchfvpv
report
activ
inocul
cell
assay
day
postinfect
follow
pseudotyp
viru
luciferas
gene
luciferas
activ
measur
use
brightglo
luciferas
assay
system
promega
accord
manufactur
protocol
glomax
promega
pseudotyp
viru
gfp
gene
supernat
replac
pb
gfpposit
cell
count
fluoresc
microscop
keyenc
infecti
unit
iu
determin
number
gfpposit
cell
cell
treat
indic
concentr
min
min
inocul
pseudotyp
virus
dmem
supplement
vv
fb
infect
determin
describ
restor
cholesterol
cell
treat
exogen
cholesterol
min
cholesterol
remov
cchf
patient
serum
sampl
obtain
center
diseas
control
prevent
atlanta
georgia
usa
two
serum
sampl
collect
healthi
japanes
adult
use
control
usag
sera
approv
research
ethic
committe
nation
institut
infecti
diseas
tokyo
japan
refer
cchfvpv
incub
dilut
human
serum
sampl
min
inocul
onto
cell
day
inocul
cchfvpv
infect
measur
describ
antibodi
stain
analysi
perform
describ
previous
antibodi
use
detect
lectin
follow
normal
mous
igg
antibodi
mous
igg
isotyp
control
r
system
antibodi
antidcsign
antibodi
clone
r
system
antilsectin
antibodi
santa
cruz
biotechnolog
inc
differ
infect
compar
use
student
ttest
examin
whether
cchfvpv
infect
characterist
recogn
authent
cchfv
infect
authent
cchfv
infect
report
depend
ph
cholesterol
first
examin
effect
increas
ph
intracellular
compart
cchfvpv
infect
shown
fig
treatment
concentr
mm
mm
decreas
cchfvpvluc
infect
dosedepend
manner
treatment
similar
effect
infect
vsvpvluc
requir
lowph
step
entri
contrast
treatment
affect
infect
mlvpvluc
independ
ph
entri
indic
cchfvpv
infect
ph
depend
next
effect
remov
cholesterol
cell
membran
investig
shown
fig
treatment
concentr
mm
mm
decreas
cchfvpvluc
infect
dosedepend
manner
shown
fig
treatment
decreas
cchfvpvluc
infect
inhibitori
effect
reduc
cholesterol
restor
ad
exogen
cholesterol
remov
cholesterol
indic
cchfvpv
infect
cholesterol
depend
furthermor
confirm
depend
cchfvpv
infect
cchfv
envelop
gp
use
sera
obtain
healthi
donor
cchf
patient
convalesc
phase
shown
fig
cchf
patient
serum
inhibit
infect
cchfvpvluc
vsvpvluc
contrast
control
sera
two
healthi
subject
affect
infect
either
two
pseudotyp
virus
result
indic
cchfvpv
infect
depend
cchfv
envelop
gp
result
suggest
entri
mechan
cchfvpv
characterist
similar
authent
cchfv
pseudotyp
therefor
like
use
investig
entri
mechan
cchfv
cchfvpv
titer
measur
jurkat
cell
found
quit
low
iuml
comparison
cell
iuml
tabl
jurkat
cell
use
investig
involv
ctype
lectin
cellsurfac
molecul
well
investig
studi
variou
viral
entri
mechan
shown
enhanc
entri
ebola
viru
lassa
viru
entri
cell
express
control
molecul
ctype
lectin
confirm
flow
cytometri
fig
shown
fig
cchfvpvgfp
lassapvgfp
infect
jurkat
cell
enhanc
express
dcsign
wherea
lsectin
express
enhanc
lassapvgfp
ebovpvgfp
infect
fig
lectin
affect
cchfvpvgfp
infect
result
show
dcsign
lsectin
involv
cchfvpv
infect
report
previous
bind
lassapv
dcsign
mainli
recogn
highmannosetyp
glycan
block
mannan
polym
mannos
cchfvpvgfp
infect
dcsignexpress
jurkat
cell
inhibit
pretreat
mannan
one
highaffin
ligand
lsectin
fig
furthermor
cchfvpvgfp
infect
also
inhibit
pretreat
antibodi
dcsign
fig
result
show
cchfvpv
may
preferenti
infect
cell
express
dcsign
result
bind
carbohydr
envelop
gp
dcsign
quantit
measur
infect
pseudotyp
vsv
viral
envelop
protein
replac
differ
viru
highli
sensit
rapid
easi
report
creation
vsv
pseudotyp
bear
envelop
protein
cchfv
requir
high
bsl
contain
experiment
use
although
pseudotyp
vsv
bear
fulllength
cchfv
envelop
gp
report
recent
intens
luminesc
express
report
use
experi
infect
cell
eight
time
higher
background
therefor
pseudotyp
viru
much
higher
titer
need
research
diagnosi
found
use
cchfv
gp
truncat
carboxyl
terminu
result
higher
titer
pseudotyp
vsv
time
higher
background
fig
although
precis
reason
truncat
carboxyl
terminu
cchfv
gp
produc
high
viral
titer
unclear
alter
local
gn
gc
andor
proper
assembl
vsv
protein
may
involv
nonetheless
high
titer
characterist
recogn
authent
cchfv
term
ph
cholesterol
depend
infect
tabl
fig
pseudotyp
vsv
truncat
cchfv
gp
eg
mutant
tabl
potenti
use
studi
entri
mechan
cchfv
serosurveil
experi
measur
neutral
activ
cchfv
requir
high
biosafeti
contain
pseudotyp
viru
power
tool
studi
cchfv
cchfv
envelop
protein
glycoprotein
phlebovirus
rift
valley
fever
viru
uukuniemi
viru
sftsv
use
ctype
lectin
dcsign
receptor
expect
ctype
lectin
receptor
cchfv
studi
found
cchfvpv
effici
infect
dcsignexpress
cell
although
examin
two
ctype
lectin
fig
indic
dcsign
possibl
novel
entri
factor
cchfv
result
suggest
role
dcsign
cell
entri
conserv
among
member
famili
bunyavirida
cchfv
initi
replic
dendrit
cell
tissu
resid
macrophag
viru
migrat
broad
rang
tissu
organ
includ
region
lymph
node
spleen
liver
dcsign
present
surfac
dendrit
cell
macrophag
result
studi
agre
tropism
viru
suggest
dcsign
import
role
infect
dendrit
cell
macrophag
howev
inhibitori
effect
mannan
antidcsign
antibodi
approxim
fig
mechan
enhanc
cchfvpv
infect
dcsign
might
nonspecif
could
involv
interact
carbohydraterecognit
domain
dcsign
effect
two
ctype
lectin
cchfvpv
infect
differ
effect
ebovpv
lassapv
infect
fig
cchfvpv
infect
enhanc
dcsign
lsectin
contrast
lassapv
infect
enhanc
lectin
ebovpv
infect
enhanc
much
greater
extent
lsectin
dcsign
differ
featur
suggest
glycosyl
statu
cchfv
envelop
gp
differ
ebola
lassa
viru
gp
howev
sever
possibl
reason
lsectin
express
enhanc
cchfvpv
infect
exampl
possibl
molecul
bind
cchfvpv
particl
result
involv
enhanc
viral
infect
second
possibl
molecul
bind
cchfvpv
particl
bind
result
enhanc
infect
due
inadequ
interact
put
factor
cofactor
necessari
infect
third
possibl
bind
cchfvpv
particl
lsectin
enhanc
transport
degrad
pathway
possibl
molecul
yet
examin
may
enhanc
cchfv
infect
dcsign
investig
entri
mechan
cchfv
precis
experi
need
includ
examin
ctype
lectin
mannos
receptor
lsign
langerin
identif
still
unknown
receptor
bind
intern
assay
addit
candid
moleculespathway
eventu
found
involv
cchfvpv
entri
cell
studi
use
wildtyp
cchfv
unclear
whether
entri
mechan
cchfvpv
cchfv
complet
ident
nevertheless
pseudotyp
viru
provid
novel
insight
mechan
cchfv
infect
develop
surrog
model
cchfv
research
